CollPlant Biotechnologies Ltd. (CLGN)
$3.91-2.74%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $51M
- Beta
- 0.76
- P/E (TTM)
- -0.42
- Short % float
- 0.43%
- Days to cover
- 1.0
- SI change
- -19.2%
- 1W
- +15.34%
- 1M
- +12.03%
- vs SPY 1W
- +15.48%
- vs SPY 1M
- +9.53%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 0
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-129.4%
REV YoY-
ROE-215.6%
EPS YoY-
ROA-173.9%
GROSS-522
OP-3901
NET-3935
[VALUATION]
P/E TTM-0.42
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.92
P/FCF-
EV/EBITDA-0.41
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E90.32
ALTMAN Z-
CURR RATIO1.57
ND/EBITDA-
BETA0.76
Company news
FAQ
- What is LOPJLB’s current signal on CLGN?
- LOPJLB’s latest quantitative signal on CollPlant Biotechnologies Ltd. (CLGN) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is CLGN in?
- CollPlant Biotechnologies Ltd. (CLGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does CollPlant Biotechnologies Ltd. (CLGN) do?
- CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, …